From November 7 to 9, 2025, the highly influential "10th Clinical Cell Immunotherapy and Hematopoietic Stem Cell Transplantation Conference" was grandly held at the Shangri-La Hotel in Wuhan. The conference brought together over a thousand top experts and scholars from top-tier hospitals, research institutions, and biopharmaceutical companies across the country to engage in in-depth discussions on core topics such as the clinical translation of cell immunotherapy and the optimization of hematopoietic stem cell transplantation. Professor Wang Jianxun from Shenzhen Cell Valley was invited to attend and delivered a keynote presentation titled "Advances in Cell Immunotherapy Research".

During the critical presentation session of the cell immunotherapy forum, Professor Wang Jianxun, drawing on a global industry perspective and integrating cutting-edge research from both domestic and international sources with the company's independent R&D practices, systematically outlined the developmental trajectory and core breakthroughs in cell immunotherapy. He pointed out that cell immunotherapy has evolved from the singular explosive growth phase of CAR-T to a new stage where multiple technological approaches such as CAR-T, CAR-NK, and TCR-T are advancing in parallel. This has achieved a leap from "difficult-to-treat" to "curable" in hematologic malignancies, while also making significant progress in the challenging field of solid tumors. However, the industry still faces common challenges, including insufficient technical standardization, low clinical translation efficiency, and the need to improve the controllability of toxic side effects for certain therapies.

Addressing these industry pain points, Professor Wang Jianxun highlighted the diversified technological layout and core achievements of Shenzhen Cell Valley Biopharmaceutical Co., Ltd. in the field of cell immunotherapy: the company has established R&D platforms covering CAR-T, CAR-NK, and CAR-γδT, among others. In the CAR-NK domain, the R&D team optimized NK cell activation signaling pathways through gene editing technology, successfully developing highly active and long-lasting CAR-NK cell lines. These cells can expand over 10,000-fold in 21 days of in vitro culture, significantly resolving production capacity limitations. In the CAR-T field, to address the high incidence of cytokine release syndrome associated with traditional products, the company has developed a next-generation enhanced product through targeted modification technology, with related clinical studies already yielding phased results.

Professor Wang Jianxun stated that in the future, Shenzhen Cell Valley Biopharmaceutical Co., Ltd. will continue to increase R&D investment in technologies such as CAR-NK, assisting clients in advancing more products into the clinical translation stage. At the same time, the company will deepen collaboration with clinical partners to jointly propel China's cell immunotherapy industry toward a new phase of high-quality development, bringing new treatment hope to cancer patients.